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New unconventional approaches to the development of antimicrobial drugs must target inhibition of
infection stages leading to host colonisation or virulence itself, rather than bacterial viability. Amongst
the most promising unconventional targets for the development of new antimicrobial drugs is bacterialeywords:
ioﬁlm
uorum sensing
ioﬁlm inhibitors
ntimicrobial therapy
adherence and bioﬁlm formation as well as their control system, the quorum-sensing (QS) system, a
mechanism of communication used to co-ordinate bacterial activities. Here we describe the evaluation
of synthetic organic compounds as bacterial bioﬁlm inhibitors against a panel of clinically relevant Gram-
positive and Gram-negative bacterial strains. This approach has successfully allowed the identiﬁcation
of ﬁve compounds (GEt, GHex, GOctad, G19 and C33) active not only against bacterial bioﬁlms but also
used
lsevieynthetic compounds displaying potential to be
© 2013 E
. Introduction
The worldwide practice of indiscriminate and continuous use of
ntibiotics for the control and prophylaxis of bacterial pathogens
as led to the development of bacterial resistance tomost available
ntimicrobials [1]. Concurrently, the rapid increase in bacte-
ial resistance to currently available antimicrobial drugs has led
esearchers to search for new sources of molecules active against
acterial pathogens, outlining a new generation of anti-infective
rug development.
A promising approach for the development of a new gen-
ration of antimicrobial drugs has arisen from the studies of
ost–pathogen interactions,which prompted a shift of drug targets
rombacterial survival topathogenicity control. Examplesofpoten-
ial non-conventional targets for microbial control are molecules
nd receptors involved in bacterial adherence to biotic and
biotic surfaces aswell as signal systemscontrollingbacterial group
∗ Corresponding author. Permanent address: Cergy-Pontoise University, Depart-
ent of Biology, 2 Av. Adolphe Chauvin, 95302 Cergy-Pontoise, France.
E-mail address: pimenta@u-cergy.fr (A. de Lima Pimenta).
924-8579/$ – see front matter © 2013 Elsevier B.V. and the International Society of Chem
ttp://dx.doi.org/10.1016/j.ijantimicag.2013.07.006as antagonists and/or inhibitors of bacterial QS.
r B.V. and the International Society of Chemotherapy. All rights reserved.
behaviour of populations organised in bioﬁlms, such as quorum
sensing (QS) [2]. In contrast to conventional antibiotics, antimi-
crobial drugs directed against such unconventional targets do not
jeopardise bacterial survival, imposing a lowselectionpressure and
thus avoiding the development of resistance [3].
One of the most promising targets is systems controlling the
early steps of bacterial adhesion, essential for the establishment
of infection and colonisation in general, as well as the subse-
quent stage of bioﬁlm formation [4]. Studies on bacterial resistance
demonstrate that when organised in bioﬁlms bacteria are able to
survive antibiotic treatments at concentrations up to a thousand
times higher than those used to kill their planktonic counterparts
[5]. Conventional antibiotic therapies may eliminate the symp-
toms of an infection by eradicating planktonic bacteria arising
from adhered populations, but are ineffective against those bacte-
ria buried in bioﬁlms, emphasising the importance of intervening
in the adhesion process to avoid bioﬁlm formation [6,7].
Experimental data have shown that bioﬁlm formation, like the
expression of many other virulence factors, responds to regulation
dependent on population density [8], e.g. QS; therefore, devel-
opment of drugs interfering with QS appears to be a promising
approach for the development of new antimicrobial drugs. Recent
otherapy. All rights reserved.
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tudies reported the identiﬁcation of different classes of com-
ounds capableof inhibitingor antagonisingbacterialQS: synthetic
alogenated furanones were identiﬁed as potent QS inhibitors to
seudomonas aeruginosa (Fig. 1a and b) [7,9]; Smith et al. identiﬁed
n antagonist of a P. aeruginosa autoinducer (AI) (Fig. 1c) [10]; and,
oon after, Geske et al. identiﬁed themost potent inhibitor reported
o date against the QS of P. aeruginosa (Fig. 1d) [11]. More recently,
sculetin (Fig. 1e) showed good activity as a QS inhibitor against
hromobacterium violaceum, Escherichia coli and P. aeruginosa [12].
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.ijantimicag.2013.
7.006.
Here we describe the identiﬁcation of new compounds capa-
le of inhibiting bioﬁlm formation of a panel of clinically
elevant Gram-positive and Gram-negative bacterial pathogens.
hese compounds, which include alkyl-esters of gallic acid,
E)-N′-benzylidene-benzohydrazides, 1,3,4-oxadiazoles and (E)-
halcones, were chosen for the present study on the basis of their
imilarity to some known QS inhibitors (Fig. 1) [7,9–12]. Quan-
iﬁcation of their activities against bioﬁlm formation, indicative
f their potential use in the control of bioﬁlm-related infections,
llowed structure–function analysis that will guide future studies
n the search for new compounds to be used for bioﬁlm control.
nalysis of cytotoxicity against human cells allowed the identiﬁca-
ion of molecules potentially suitable for the development of new
ntibioﬁlm drugs for therapeutic purposes.
. Materials and methods
.1. Bacterial strains
Standard reference strains Enterococcus faecalis ATCC 19433, P.
eruginosa ATCC 27853, Staphylococcus aureus ATCC 25923, Staphy-
ococcus epidermidis ATCC 35547 and Streptococcus mutans ATCC
5175 were used in this study. Isolates were kept in trypticase soy
roth (TSB) supplemented with 20% (v/v) glycerol at −20 ◦C and
ere routinely cultivated in TSB. Conditions for the best bioﬁlm
roduction were established for each strain (data not shown) and
re mentioned when necessary.
.2. Synthesis and puriﬁcation of the compounds
Reagents were obtained commercially from Sigma–Aldrich
St. Louis, MO) and solvents were from Vetec (Duque de Cax-
as, Brazil). Exceptions were 3,4,5-trimethoxybenzohydrazide,
,4,5-trimethoxyacetophenone and 3-methoxy-4-(phenylmetho-
y)-benzaldehyde, prepared as previously described [13–15], with
ields of 80%, 81% and 88%, respectively.
All alkyl-esters of gallic acid were synthesised and charac-
erised as previously described [16]. Gallic acid (5mmol) and the
orresponding alcohol (15mmol) were mixed. For compounds
Met, GEt, GProp, GBut and GHex, the mixture was dissolved in
oluene (70mL) and concentrated sulphuric acid (0.4mL), heated
or 8–12h in reﬂux using a Dean–Stark apparatus, and the sol-
ent was removed under reduced pressure. For compounds GOct
nd GOctad, the mixture was dissolved in dioxane (10mL) and p-
oluenesulfonic acid (0.3mL) and heated for 2–4h in bath oil under
acuum. All products were puriﬁed by column chromatography.
The (E)-N′-benzylidene-benzohydrazides were synthesised as
reviously described [17,18] by condensation of the benzohy-
razide (2mmol) or 3,4,5-trimethoxy-benzohydrazide (2mmol)
ith the appropriate aldehyde (2mmol) in methanol (15mL) and
eﬂuxing for 2h. After cooling, the crude product was collected
y ﬁltration, washed and recrystallised from hot ethanol to give
hite solids. The compounds G1, G8, G23 and G24 have beenf Antimicrobial Agents 42 (2013) 519–523
previously described [14] and compounds G7, G19 and F41 were
recently patented by our group [19].
The 1,3,4-oxadiazoles were prepared by cyclisation of the pre-
viously obtained (E)-N′-benzylidene-benzohydrazides with acetic
anhydride under reﬂux for 3h as described previously [20]. After
cooling, the crude product was collected by ﬁltration, washed and
recrystallised from acetone/water to give white solids. The com-
pounds Y18, Z43 and Z47 have been previously described [21] and
compounds Z5 and Z8 were recently patented by our group [19].
The (E)-chalcones were prepared by aldol condensation using
methanol as solvent under basic conditions (KOH50%,w/v) at room
temperature for 24h. Distilled water and 10% hydrochloric acid
were added to the reaction for total precipitationof the compounds,
which were then obtained by vacuum ﬁltration and later recrys-
tallised in dichloromethane and hexane. All structures (C1, C6, C7,
C24, C28, C33, C37, L15, L48, L50, J4, J61, J62, Lou5, R58 and R61)
were previously described by our group [21–23].
2.3. Bacterial growth and bioﬁlm inhibition assays
Bioﬁlm production and quantiﬁcation assays were performed
by colorimetric assay as described previously [24]. No antibiotics
were added at any point during these assays. To assay for bioﬁlm
inhibition, bacterial strains were grown statically for 20h at 37 ◦C
in TSB. Polystyrene 96-well microtitre plates were then inocu-
lated with 100L/well of bacterial suspension previously diluted
to 5×108 CFU/mL in TSB supplemented with 4% sucrose (w/v)
and 3.5% (v/v) dimethyl sulphoxide (DMSO). Then, 100L of the
compound tobe tested for antibioﬁlmactivity, prepared in TSB sup-
plemented with 4% sucrose (w/v) and 3.5% (v/v) DMSO, was added
to theﬁrstwell. Afterhomogenisationbypipettingupanddownthe
200L content of the well, 100L of this mixture was transferred
to the next well and the procedure was repeated until a ﬁnal con-
centration of 0.2g/mL was reached, and the ﬁnal volume of each
well was 100L. Microtitre plates were incubated for 20h at 37 ◦C
in a humidiﬁed chamber and bacterial growth was quantiﬁed by
absorbance at 630nm to assess eventual growth inhibition. Bacte-
rial suspensionswerediscardedandbioﬁlmwas stainedwith a0.1%
(w/v) crystal violet solution for quantiﬁcation. After solubilisation
of crystal violet in 1% sodium dodecyl sulphate (SDS), bioﬁlm was
quantiﬁed by measuring the absorbance at 595nm. For S. mutans
assays, incubation was performed in microaerophilic conditions.
Eventual growth inhibition was accessed for each compound by
reading the optical density at 600nm before bioﬁlm quantiﬁcation.
Growth inhibition,when identiﬁed,wasconsideredasan indication
of potential conventional antibacterial properties of the chemical
compounds, and those compounds were selected for future inves-
tigation.
2.4. Cell culture and selectivity assays
Selectivity towards bacteria of molecules positive for bioﬁlm
inhibition was evaluated using the human glioma cell line A172
by the MTT (thialyl blue tetrazolium bromide) colorimetric assay
as previously described [25]. Brieﬂy, A172 cells were cultured in
Dulbecco’s Modiﬁed Eagle Medium: nutrient mixture F-12 sup-
plemented with 10% foetal bovine serum in 25 cm2 culture ﬂasks
at 37 ◦C in a humidiﬁed atmosphere of 5% CO2. Cells were plated
in 96-well plates and were subsequently exposed for 24h to the
compounds for cytotoxicity assays. Cell viability was quantiﬁed
by MTT colorimetric assay. Absorbance was measured at 540nm
and results were expressed as percentage viability of the control
samples.
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.5. Statistical analysis
The signiﬁcance of differences was evaluated by means of one-
ay analysis of variance (ANOVA) with the Newman–Keuls post
est using GraphPad InStat software (GraphPad Software Inc., La
olla, CA). The level of signiﬁcance was set at P<0.05 in all cases.
. Results
.1. Synthesis of the compounds
All tested compounds (Table 1) were previously prepared by
ur research group, with yields ranging between 21% and 99%
16,19,21–23].
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.ijantimicag.2013.
7.006.
.2. Quantiﬁcation of bioﬁlm inhibition activities
Table 2 shows the results of bioﬁlm inhibition for each assayed
ompound as well as the concentrations at which these inhibi-
ions levels were observed (indicated in brackets). All experiments
ere performed in triplicate,with themeanand standarddeviation
hown in Table 2.
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.ijantimicag.2013.
7.006.
.3. Cytotoxicity of compounds active against bioﬁlm
Cytotoxicity assays against human glioma A172 cells were per-
ormedwith compounds at the concentrationwhere theydisplayed
aximum antibioﬁlm activity (indicated in brackets in Table 2).
esults obtained for cytotoxicity are summarised in Table 3.
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.ijantimicag.2013.
7.006.
. Discussion
The criteria for determining the structures of synthesised and
ested compounds (Table 1) for bioﬁlm inhibition followed the
rinciple of molecular similarity, favouring either molecular struc-
ures similar to QS inhibitors described in the literature (Fig. 1)
7,9–12,26] or structures derived fromthosewith reported antibac-
erial activities [21]. Bioﬁlm inhibition rates were calculated using
he mean bioﬁlm production obtained in each experiment per-
ormed in triplicate (Table 2). Inhibition levels >50% were generally
isible to the naked eye.
The results of bioﬁlm inhibition assays for alkyl-esters of gallic
cid (Table 2) showed that, in general, Gram-positive bacteria
ere the most susceptible to this class of compounds. Regarding
pecies speciﬁcity, amongst the Gram-positives, E. faecalis and S.
ureus showed sensitivity to most of the alkyl-esters of gallic acid
ested. Methyl gallate (GMet) was the only derivative displaying
ctivity against bioﬁlms of all evaluated bacterial strains. Increases
n compound hydrophobicity, as result of increases in the size of
heir carbon side chains, did not appear to interfere with their
ctivities against bioﬁlms of E. faecalis and S. aureus, suggesting
hat the three hydroxyl groups at the phenyl ring correspond to the
mportant portion of the molecule for activity (pharmacophore).
his information is supported by Ni et al. who evaluated pyrogallol
erivatives, compounds that also have the trihydroxyphenyl ring,
nd showed that they confer QS antagonist activity inVibrio harveyif Antimicrobial Agents 42 (2013) 519–523 521
[27]. However, increases in the hydrophobicity of alkyl-esters of
gallic acid did affect their activities speciﬁcally against bioﬁlm
of S. mutans, as the 91% inhibition activity displayed by methyl
gallate (GMet) decreased to <10% with the increasing of carbon
side chains. The results described by Ni et al. [27] with pyrogallol
derivatives on the activity of AI-2 suggest that the mechanism of
bioﬁlm inhibition of alkyl-esters of gallic acid occurs through an
antagonistic effect on AI-2 or its receptor, LuxP [28]. Based on the
concept of molecular mimicry, it is possible that other compounds
capable of complexing to boric acid could potentially bind to LuxP,
acting as QS inhibitors, as in the case of alkyl-esters of gallic acid,
and possibly some (E)-N′-benzylidene-benzohydrazides assayed.
Table 2 also summarises the results of bioﬁlm inhibition
obtained for (E)-N′-benzylidene-benzohydrazides. Compounds
without substituents at the phenyl A ring were more active against
most of the Gram-positive species tested (E. faecalis, S. aureus and
S. epidermidis). Interestingly, simultaneous addition of trimethoxy
substituents at positions 3, 4 and 5 in the A ring (F41) shifts this
bioﬁlm inhibitory effect towards S. mutans and P. aeruginosa, with
activity against the other bacterial strains being completely lost.
The different effects of these N′-benzylidene-benzohydrazides on
bioﬁlms of Gram-positive species compared with P. aeruginosa
(Gram-negative) allow speculation about its mechanism of inhi-
bition. Both in Gram-positive and Gram-negative bacteria, bioﬁlm
is primarily regulated by QS. However, whilst Gram-negative
bacteria generally use acylated homoserine lactone deriva-
tives as autoinducers (AI-1), Gram-positive bacteria typically
respond to modiﬁed peptides (AIP). Results obtained here
with (E)-N′-benzylidene-benzohydrazides suggest that these com-
pounds exert an effect on bioﬁlm through antagonism of the QS
pathway mediated by AIPs, showing weak or no antagonist effect
on Gram-negative AI-1-mediated QS [8]. In the case of compounds
G7, G19 and F41, which showed activity both on Gram-positive
and Gram-negative bioﬁlms, the mechanism of inhibition of these
(E)-N′-benzylidene-benzohydrazides might occur through the uni-
versal system of QS, possibly by antagonising the action of AI-2,
similar to the alkyl-esters of gallic acid. The best inhibitory activi-
tieswere displayed by compoundG23 (which has a hydroxyl group
in position 2 and a bromine atom at position 5 of the B ring), com-
pound G7 (with a hydroxyl group in position 4 and a nitro group
in position 3 of the B ring) and compound G19 (with a bromine
atom in position 4 of the B ring). Interestingly, when the B ring
is a 2-chloroquinoline group (G1) the compound shows moder-
ate activity, and it becomes inactive when the B ring is replaced
by the 4-CF3-phenyl group (a hydrophobic group, strong electron-
withdrawing) (G24) or is replaced by the 3-pyridine group (G8).
These observations suggest that the balance between hydropho-
bicity (bromine or nitro, bulky and electron-withdrawing groups)
and hydrophilicity (hydroxyl, electron donor group) in the B ring
might be an important factor for the activity of (E)-N′-benzylidene-
benzohydrazides (G7 andG23), when the ring A is the phenyl group
without substituents. It is interesting to note that some furanones,
important QS inhibitors described in the literature, also have a
bromine atom whose presence is important for antibioﬁlm activity
(Fig. 1) [7,9,11,28].
Comparedwith (E)-N′-benzylidene-benzohydrazides, the 1,3,4-
oxadiazoles are more rigid structures owing to the central
heterocyclic ring. This rigidity apparently confers loss of activity
of the compounds. The most sensitive species to 1,3,4-oxadiazoles
was S. aureus (Table 2). Compounds of this class with methoxyl
groups (Z8, Z43 and Z47) or without substituents at the A ring
(Y18) were not active against bioﬁlm. Only compound Z5 showed
signiﬁcant bioﬁlm inhibitory activity without interfering with
bacterial growth. Similar to that observed for (E)-N′-benzylidene-
benzohydrazides, apparently the ring B substituted by a bromine
atom (at position 5) and a hydroxyl group (at position 4),
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ollowed in this casebyamethoxyl group inposition3, favoured the
ctivity against bioﬁlm (Z5). Again, the balance betweenhydropho-
icity (bromine, a electron-withdrawing and bulky group) and
ydrophilicity (hydroxyl and methoxyl, electron donor groups) in
he B ring appears to be important for activity (Z5), as well as
he presence of methoxyl groups at positions 3, 4 and 5 in the A
ing. Compounds with chlorine atoms (electron-withdrawing sub-
tituents) in the B ring (Z43 and Z47), even at position 3, or the
-naphthyl group (hydrophobic) as B ring (Z8), exhibited weak
ctivity against bioﬁlm, although interfering with bacterial growth
Z43 and Z47). These ﬁndings suggest that the presence of only
lectron-withdrawing groups at the B ring (Z43 and Z47) or a
ydrophobic B ring (Z8) does not favour 1,3,4-oxadiazole activity
gainst bioﬁlms.
Results of bioﬁlm inhibition obtained for (E)-chalcones (Table
) showed that these compounds exhibit greater bioﬁlm activity
gainst Gram-positive species, although C7 was capable of inhibi-
ing P. aeruginosa bioﬁlm at a 56% rate. Moreover, this compound,
hich has as substituent the imidazole group at position 4 of the A
ing, and the 2-naphthyl group as B ring,was active against bioﬁlms
f all strains tested, showing excellent rates of inhibition, espe-
ially against S. aureus, S. epidermidis and P. aeruginosa, being less
ffective against E. faecalis. This compound exhibits a strong elec-
ronic conjugation, which seems to be related to its antibioﬁlm
ctivity.However,when theB ring is substitutedby the3-methoxy-
-(phenylmethoxy)-phenyl group (R58), the activity is reduced.
hese observations appear to indicate that the A ring with sub-
tituents in conjugation with the carbonyl group, and the presence
f a planar and hydrophobic/lipophilic B ring (2-naphthyl), appears
o be crucial for antibioﬁlm activity of the (E)-chalcones. The (E)-
halcones with methoxyl groups at positions 2, 4 and 5 of the A
ing and the 2-naphthyl (J4) or 2-chloroquinoline (J61 and J62)
roup as B ring did not show antibioﬁlm activity. However, com-
ound L48, which has the 3,4-methylenedioxy-phenyl group as A
ing, and also the 2-chloroquinoline group as B ring, showed excel-
ent activity. Amongst the (E)-chalcones L15 and L50, also with the
,4-methylenedioxy-phenyl group as A ring, the highest bioﬁlm
nhibitory activity was displayed by the compound with the 2-
aphthyl group as B ring (L15). These ﬁndings demonstrate once
gain the importance of the presence of the hydrophobic/lipophilic
ring (quinoline or 2-naphthyl groups) associated with the 3,4-
ethylenedioxy group as the substituent of the A ring for the good
ctivity of this class of compounds. In general, (E)-chalcones with
hree methoxyl groups at the A ring showed moderate (C24 and J4)
r no activity (J61 and J62) against bacterial bioﬁlm, even when the
ring is the 2-naphthyl group (C24 and J4), indicating that steric
ffects due to these substituents might be reducing the antibioﬁlm
ctivity. However, when the B ring is the 2-naphthyl group, the
resenceof one (C28) or two (C1,C6,C33 andC37)methoxyl groups
t the A ring favours the antibioﬁlm activity, especially when these
re in position 3 (C1, C6 and C33). The (E)-chalcone C37, with
ethoxyl groups in positions 2 and 5 of the A ring, showed moder-
te activity for S. aureus and S.mutansbioﬁlms.When theB ringwas
eplaced by a nitrogenated heterocycle substituted with a 3-CF3-
henyl group, the activity against S. mutans is drastically reduced
Lou5). Similar results were observed for the (E)-N′-benzylidene-
enzohydrazides, where compounds with the CF3 substituent at
he B ring (G24) did not show activity against any of the tested
trains. When the A ring is the 2-chlorotiophen group (non-polar)
nd the B ring is the 3-methoxy-4-(phenylmethoxy)-phenyl group,
he (E)-chalcone also showed low activity (R61). Taken together,
hese observations allow us to conclude that the activity of the
E)-chalcones against bioﬁlm is dependent on steric and electronic
actors, with the following structural characteristics appearing as
mportant for this activity: (i) A ring with substituents in con-
unction with the carbonyl group, such as 4-phenyl-imidazole; (ii)f Antimicrobial Agents 42 (2013) 519–523
substituents able to make hydrogen bonds in the A ring, such as
3,4-methylenedioxy group or one or two methoxyl groups; and
(iii) hydrophobic/polar B ring. Conversely, the results indicate that
either the presence of three methoxyl groups in the A ring, or a
non-polar A ring, did not favour the antibioﬁlm activity of the (E)-
chalcones.
Compounds showing bioﬁlm inhibition levels ≥50% were
selected for further evaluation of their selectivity towards bacteria
using human glioma A172 cells. Selectivity assays were performed
with compounds at the concentration where they displayed max-
imum antibioﬁlm activity (indicated in brackets in Table 2). The
results obtained are summarised in Table 3 and demonstrate that
amongst the alkyl-esters of gallic acid tested, compounds GEt,
GHex and GOctad showed no cytotoxicity against human glioma
A172 cells, thus suggesting that their activity is selectively directed
against bacteria. Amongst these compounds, GOctad was the one
showing the best bioﬁlm inhibitory activity (75% inhibition against
S. aureus) (Table 2). Compounds GMet and GOct, although show-
ing the best bioﬁlm inhibitory activities amongst the alkyl-esters
of gallic acid tested, were toxic against human cells, precluding
their potential therapeutic use in bioﬁlm control. In the (E)-N′-
benzylidene-benzohydrazide group, results indicate compound
G19 (61% bioﬁlm inhibition against S. aureus) as the best candidate
for use in bioﬁlm therapeutics. Compound G23, although showing
thebestbioﬁlm inhibitoryactivity amongst the (E)-N′-benzylidene-
benzohydrazides, showed high cytotoxicity levels against human
cells. Compound Z5 was the only 1,3,4-oxadiazol showing signif-
icant bioﬁlm inhibition activity and it also displayed a high level
of cytotoxicity against human cells, excluding this group of com-
pounds frompotential therapeutic use for bioﬁlm control. Amongst
the (E)-chalcones tested, compound C33, which inhibited S. mutans
bioﬁlm at a rate of 70%, was the least toxic against human glioma
A172 cells, followed by compound L48, active against bioﬁlms of E.
faecalis (89% inhibition), S. aureus (66% inhibition) and S. epidermidis
(85% inhibition). These results indicate that compounds GEt, GHex,
GOctad, G19 and C33 are selective for bacterial bioﬁlms and do not
show toxicity against human glioma A172 cells. Further studies are
needed to access the overall toxicity of these compounds, which
will be conducted and presented in a future work, with in vivo
assessments.
The results obtained here revealed that the steric and elec-
tronic characteristics favouring the bioﬁlm inhibitory activity of
(E)-chalcones are different from those that favour the activity of
(E)-N′-benzylidene-benzohydrazides, 1,3,4-oxadiazoles and alkyl-
esters of gallic acid. To (E)-chalcones, the presence of substituents
in conjunction with the carbonyl group or the ability to make
hydrogen bonds in the A ring, as well as a hydrophobic/polar
B ring, is important. To (E)-N′-benzylidene-benzohydrazides
and 1,3,4-oxadiazoles, the balance between hydrophobicity and
hydrophilicity in the B ring appears to be important for antibioﬁlm
activity, although the oxadiazoles are more rigid structures com-
pared with their precursors (E)-N′-benzylidene-benzohydrazides
and this rigidity apparently confers loss of activity of this class
of compounds. Finally, for the alkyl-esters of gallic acid, results
suggest that the portion of the molecule important for its activity
comprises the three hydroxyls groups at the phenyl ring, and that
hydrophobicity apparently does not appear to induce a change in
activity.
It is important to note that toxicity towards human gliomaA172
cells of compoundswith signiﬁcant bioﬁlm inhibition activity iden-
tiﬁed here, although being a drawback for their use in therapeutics,
does not preclude their potential development for the function-
alisation of materials used for other purposes, such as biofouling
control in closed systems. Evaluation of such potential for some
compounds identiﬁed here is currently under study, and studies
on the mechanisms of bioﬁlm inhibition are underway to evaluate
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he potential use of the more active and selective compounds (GEt,
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ore, ongoing studies in our laboratory to consolidate thepotential
se of these compounds, shown here as active against bioﬁlm for-
ation, include tests against a range of bacterial isolates, as well as
linical strains, chosen in accordance with their foreseen applica-
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